Global X Management Co. LLC lifted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 41.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 5,897 shares of the medical instruments supplier’s stock after purchasing an additional 1,722 shares during the quarter. Global X Management Co. LLC’s holdings in Becton Dickinson and were worth $1,262,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Legacy Advisors LLC increased its holdings in shares of Becton Dickinson and by 7,000.0% during the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock worth $106,000 after buying an additional 490 shares in the last quarter. FTB Advisors Inc. increased its holdings in shares of Becton Dickinson and by 114.2% during the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 290 shares in the last quarter. Penserra Capital Management LLC acquired a new position in shares of Becton Dickinson and during the fourth quarter worth $136,000. Exane Derivatives grew its stake in shares of Becton Dickinson and by 848.6% in the fourth quarter. Exane Derivatives now owns 702 shares of the medical instruments supplier’s stock worth $150,000 after purchasing an additional 628 shares during the last quarter. Finally, Meeder Asset Management Inc. bought a new stake in shares of Becton Dickinson and in the fourth quarter worth $160,000. Institutional investors own 77.50% of the company’s stock.
Shares of Becton Dickinson and Co (BDX) opened at $222.87 on Monday. The company has a current ratio of 1.54, a quick ratio of 0.93 and a debt-to-equity ratio of 1.04. The company has a market cap of $59,337.46, a price-to-earnings ratio of 23.12, a price-to-earnings-growth ratio of 1.59 and a beta of 1.12. Becton Dickinson and Co has a 1 year low of $175.66 and a 1 year high of $248.39.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be given a dividend of $0.75 per share. The ex-dividend date of this dividend is Thursday, March 8th. This represents a $3.00 dividend on an annualized basis and a yield of 1.35%. Becton Dickinson and’s dividend payout ratio (DPR) is currently 229.01%.
Several analysts recently weighed in on the stock. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price objective on the stock in a research note on Tuesday, October 31st. Morgan Stanley boosted their price objective on shares of Becton Dickinson and from $245.00 to $250.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 7th. Bank of America reissued a “buy” rating and issued a $260.00 price objective on shares of Becton Dickinson and in a research note on Friday, January 19th. Piper Jaffray Companies reissued an “overweight” rating and issued a $260.00 price objective (up previously from $223.00) on shares of Becton Dickinson and in a research note on Tuesday, February 6th. Finally, Evercore ISI assumed coverage on shares of Becton Dickinson and in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $245.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $237.27.
In other Becton Dickinson and news, Director Timothy M. Ring sold 269,661 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the sale, the director now owns 295,753 shares of the company’s stock, valued at $64,420,918.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.00% of the company’s stock.
Becton Dickinson and Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.